Mylan Pharmaceuticals spent the past decade raising the price of the EpiPen from $57 to $600 . Why? Because they could. The company didn’t have any genuine competition. And now one competitor,Teva Pharmaceuticals, a company that has tried and failed to bring a generic EpiPen to market before, or says that their product won’t be alert until late 2017 or even 2018.
Read more...
Source: gawker.com